(Total Views: 411)
Posted On: 05/22/2018 7:58:55 AM
Post# of 30015
![Avatar](https://investorshangout.com/images/ProfileImages/1127985187_4760_B2E026AE-DECC-4544-A79A-764E58499F5C.jpeg)
Amarantus Retains Weild & Co. to Advise on JOBS Act Funding
MAY 22, 2018
Mr. Heng Fai Chan converts secured debt into common equity
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it retained Weild & Co. to advise the Company for planned capital raises using mechanisms created under the JOBS Act. The Company is evaluating strategies to capitalize both the parent company Amarantus, as well as subsidiaries Elto Pharma, Inc., Cutanogen Corporations and MANF Therapeutics.
"Weild & Co., led by Mr. David Weild, brings tremendous experience in the capital markets, and specifically understands newly-created mechanisms under the JOBS Act that allow for Alternate Reporting companies such as Amarantus to gain access to pools of capital that were previously unreachable for us," said Gerald E. Commissiong, President & CEO of Amarantus.
Mr. Weild is Founder, Chairman and CEO of Weild & Co. The studies that he co-authored have documented the long-term decline in equity capital formation in the United States and provided the core arguments that gave rise to the JOBS Act and many of the specific provisions contained in the JOBS Act. For these reasons, he is frequently called "The father of the JOBS Act." Mr. Weild is a former Vice Chairman and executive committee member of The NASDAQ Stock Market and spent years running major Wall Street investment banking and equity capital markets businesses. He holds an MBA from the Stern School of Business and a BA from Wesleyan University. He studied on exchange at The Sorbonne, Ecole des Haute Etudes Commerciales and The Stockholm School of Economics. He is also the Chairman Emeritus and a Board Member of Tuesday's Children, the charity that provides long-term recovery services to 9/11 family members, first responders, and widows and orphans of US military.
"Amarantus has acquired some very important product candidates that have the potential to improve outcomes for some of the most challenging human health conditions, including Parkinson's and severe burns," said David Weild, Chairman & CEO of Weild & Co. "We look forward to helping the management team prepare offerings that have the potential to be accretive to shareholder value."
Concurrent with this announcement, the Company disclosed that Mr. Heng Fai Chan's affiliated entities, including Xpress Group International, have converted their $350,000 senior secured convertible debenture into common stock of Amarantus. Mr. Chan and affiliated entities now own 72,610,667 shares of common stock, representing approximately 37% of the outstanding common stock of Amarantus.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)